The European Patent Office (EPO) has granted patent EP3610027B1, titled "GLUCOAMYLASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME." This patent relates to specific variants of glucoamylase enzymes and the genetic material that codes for them, with potential applications in biotechnology and industrial processes. The patent is designated for a number of European states and has an effective date of March 18, 2026.

This grant signifies a new intellectual property right for the inventors and their associated entities. For companies operating in the biotechnology and pharmaceutical sectors, particularly those involved in enzyme production or genetic engineering, this patent may impact their freedom to operate or necessitate licensing agreements. Compliance officers should note the effective date and the designated states, ensuring awareness of any potential IP landscape changes relevant to their organization's research, development, or manufacturing activities.